

Children's Mercy Kansas City

SHARE @ Children's Mercy

Posters

10-2023

Latency Time From Prior Authorization Submission To Initiation Of Biologic Therapy In Inflammatory Bowel Disease

Shannon Capraro

Janelle R. Noel-Macdonnell PhD

Lauren Disselhoff

Layne Sieve

Rachel Chevalier

Let us know how access to this publication benefits you

Follow this and additional works at: <https://scholarlyexchange.childrensmercy.org/posters>



Part of the [Gastroenterology Commons](#), and the [Pediatrics Commons](#)

INTRODUCTION

- Initiating biologic therapy in patients with IBD is important for disease control
- **We investigate which factors contribute to time to biologic initiation**



METHOD

- Analysis of outpatient biologic therapy initiation in 102 patients
- Descriptive statistics with bivariate summaries
- Wilcoxon Rank Sum Tests and Kruskal-Wallis Tests

DISCUSSION

- Early biologic initiation delays disease progression
- Illness severity or insurance type do not increase lag time

IBD patients wait 2 weeks or longer AFTER prior authorization submission to receive biologic therapy




Shannon Capraro MD¹; Janelle Noel-MacDonnell PhD^{1,2}; Lauren Disselhoff RN¹; Layne Sieve RN¹; Rachel Chevalier MD^{1,2}

1 Children's Mercy Kansas City; 2 University of Missouri Kansas City


RESULTS

- Demographics (n=102)
- 47% Female
- 77.5% White
- Median PUCAI 15 (IQR: 0, 25)

Biologic Therapy Choice



Insurance Status



- Median time from PA to first dose is 15 days (IQR: 12, 24)
- No difference in insurance status to receive first dose (p=0.695)

